# Kevin Parker

> Kevin Parker, Ph.D. is the co-founder and CEO of Cartography Biosciences, a South San Francisco-based oncology company using single-cell genomics and AI to map the tumor antigen landscape and build precision immunotherapies. A Harvard and Stanford alumnus who founded the company straight out of his PhD, Parker has raised $124M in total funding, struck a landmark collaboration with Gilead Sciences, received FDA IND approval for his lead drug CBI-1214, and dosed the first patient in a Phase 1 colorectal cancer trial in early 2026 - all before most scientists finish a second postdoc.

- **Role:** Co-Founder & CEO at Cartography Biosciences
- **Organizations:** Cartography Biosciences
- **Nationality:** American
- **Education:** B.A. in Human Developmental and Regenerative Biology, Harvard University, Ph.D. in Stem Cell Biology and Regenerative Medicine (Genomics, Immunology, Computational Biology), Stanford University
- **Known for:** Co-founded Cartography Biosciences and raised $124M in total funding, Named to Forbes 30 Under 30 (Healthcare, 2022 list), Named to Endpoints News 20 Under 40 (2023)

## Career timeline

- **2012-2016** — Undergraduate at Harvard University; conducted stem cell research under Kevin Eggan
- **2016-2020** — Ph.D. student at Stanford University co-mentored by Howard Chang and Ansu Satpathy; developed expertise in single-cell ATAC-sequencing and functional genomics
- **2020** — Co-founded Cartography Biosciences with Howard Chang and Ansu Satpathy
- **2022** — Raised $57M combined seed and Series A financing led by 8VC; company came out of stealth
- **2022** — Named to Forbes 30 Under 30 (Healthcare)
- **2023** — Named to Endpoints News 20 Under 40 list; company won Best Places to Work in Bay Area award
- **2024** — Announced strategic collaboration with Gilead Sciences for TNBC and NSCLC programs; received $20M upfront payment
- **2025-10** — Closed $67M Series B financing led by Pfizer Ventures with LG Corp, Amgen Ventures, and existing investors
- **2025-12** — CBI-1214 received FDA IND approval and Fast Track designation for colorectal cancer
- **2026-02** — Dosed first patient in Phase 1 trial of CBI-1214 for colorectal cancer
- **2026-04** — Gilead exercised first option target under strategic collaboration agreement

## Achievements

- Co-founded Cartography Biosciences and raised $124M in total funding
- Named to Forbes 30 Under 30 (Healthcare, 2022 list)
- Named to Endpoints News 20 Under 40 (2023)
- Led company to $20M Gilead Sciences strategic collaboration for TNBC and NSCLC (2024)
- Obtained FDA IND approval and Fast Track designation for lead drug CBI-1214 (December 2025)
- Dosed first patient in Phase 1 colorectal cancer trial of CBI-1214 (February 2026)
- Built ATLAS and SUMMIT platforms processing petabyte-scale single-cell sequencing data
- Grew Cartography from 2 co-founders to 63 employees in under 6 years
- Published research in Cell and Science journals during PhD
- Won San Francisco Business Times Best Places to Work in Bay Area award (2023)

## Latest updates

- **2026-04** — Gilead Sciences exercised its first option target under its strategic collaboration with Cartography, validating the ATLAS and SUMMIT platforms for TNBC and NSCLC programs.
- **2026-02** — Cartography Biosciences dosed its first patient in a Phase 1 clinical trial of CBI-1214, a T-cell engager targeting LY6G6D for microsatellite stable colorectal cancer.
- **2025-12** — CBI-1214 received FDA Investigational New Drug (IND) approval and Fast Track designation for colorectal cancer.
- **2025-10** — Closed $67M Series B financing led by Pfizer Ventures, joined by LG Corp, Amgen Ventures, Finchley H.V., Global BioAccess Fund, and Lotte Holdings CVC alongside existing investors a16z, 8VC, and Wing VC.

## Links

- Website: https://cartography.bio
- LinkedIn: http://www.linkedin.com/in/kevin-parker-584a1089
- Twitter/X: https://twitter.com/CartographyBio

---

Profile page: https://yespress.io/kevin-parker
Published by YesPress — https://yespress.io
Last updated: 2026-05-07